Sirona Biochem Billion Dollar Skin Lightening Opportunity With TFC-1067 Compound
Sirona Biochem is the center of attention on signing a landmark licensing deal for its proprietary skin-lightening compound with a company topping billions of dollars in sales. The signing of the deal comes at a time of growing demand for skin lightening products with the market poised to reach $20 billion by 2022.
Sirona | Rodan + Field Deal
The cosmetic ingredient and drug discovery company remain well positioned to generate significant value on the burgeoning skin lightening market. Backed by a proprietary platform technology that has already given rise to TFC-1067, the company is already eliciting strong interest from some of the biggest skin care brands.
The signing of a term sheet with Rodan + Fields LLC for proprietary TFC-1067 compound might as well have opened the door for the company to generate significant value going forward. Under the terms of the agreement, Sirona Biochem is to manufacture and supply TFC-1067 for use by Rodan + Fields in its products.
The company stands to generate significant revenues on the sale of the skin-lightening compound. In addition, it is entitled to a fee by Rodan + Fields on the signing of the definitive agreement. The company will also earn milestone fees on each product that Rodan + Fields sales, utilizing the skin-lightening agent TFC-1067. The two have also agreed to establish regular formal meetings to explore future opportunities.
A partnership with Rodan + Fields marks an important milestone as Sirona Biochem seeks to generate significant value from its proprietary skin lighting compound. Skincare brand Rodan + Fields has generated more than $1 billion in sales since 2016, seen as an ideal partner for Sirona after years of TFC-1067 R&D investments.
The compound stands out in part because it is superior to current actives in the market in addition to being safe and free of hydroquinone. TFC-1067 has also proved to be superior in the treatment of dyschromia with no adverse effects.
The use of TFC-1067 in Rodan + Fields products opens the door for Sirona Biochem to recoup a substantial amount of money spent on the development of the skin lighting agent.
“After many years of developing TFC-1067 with the support of the French government and European Union in the Cosmetic Valley, France, we are excited to partner with skincare industry leader Rodan + Fields. This marks an important milestone for Sirona Biochem,” explained Dr. Howard Verrico CEO of Sirona Biochem.
Skin Lightening Opportunity
Sirona Biochem is on the cusp of something great in the skin care market. The company has already secured a U.S patent for the flagship skin-lightening agent TFC-1067 further strengthening its IP portfolio. The new patent adds to similar patents granted in Germany, France, and the United Kingdom.
With the patent, the company can now pursue licensing deals similar to the one signed with Rodan + Fields. Such deals should go a long way in helping the company strengthen its revenue streams through licensing fees as well as milestone fees and royalty payments.
Sirona Biochem is currently in advanced negotiations in North America and Asia as it eyes licensing deals for the skin-lightening compound. Given the potential impact of TFC-1067 in the multi-billion dollar skin lightening market, the company could be a potential acquisition target for big companies wishing to own TFC-1067 outright.
- Published in Bio technology, Dermatology, Sirona Biochem, Skin Care
Sirona Biochem Announces Receipt of $500,000 US Milestone Payment
Momentum Public Relations
Press Release: January 29, 2018
Sirona Biochem Corp. (TSX VENTURE: SBM)(FRANKFURT: ZSB)(XETRA: ZSB) (the “Company”) is pleased to announce that the $500,000 USD payment from Wanbang Biopharmaceuticals has been received.
The Company now awaits the China Food and Drug Administration (CFDA) approval of the IND filing, which will lead to a clinical trial of Sirona’s SGLT2 inhibitor for diabetes. The CFDA is required to respond to the submission no later than sixty days after filing. Filing took place December 27th, 2017. The acceptance of the IND application by the CFDA, will trigger another $500,000 USD milestone payment to Sirona Biochem.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Sirona Biochem